Characteristics of Patients Treated With Secukinumab for Mod... | Clinical Trial | StuddyBuddy@endsection Characteristics of Patients Treated With Secukinumab for Moderate to Severe Plaque Psoriasis
Join us at Health Research Day — June 6th at Canton Waterfront Park, Baltimore!   Learn More →
← Back to all trials
Completed NCT05650060

Characteristics of Patients Treated With Secukinumab for Moderate to Severe Plaque Psoriasis

Conditions: Plaque Psoriasis

Sex: All
Ages: 18 Years – N/A
Enrollment: 163
Sponsor: Novartis Pharmaceuticals

Location: Thailand

Summary

This study was a non-interventional, retrospective study collecting data from hospital medical records. Approximately 200 adult patients with moderate to severe plaque psoriasis who were treated with secukinumab from hospitals in Thailand that participated in this study were expected for data collection.

Eligibility Criteria

Inclusion Criteria:Adult male or female aged ≥ 18 years at index datePrevious diagnosis of moderate to severe plaque psoriasis as hospital record with available baseline PASI at index date (date 0 to date -7 prior index date)Initiated treatment with secukinumab for moderate to severe plaque psoriasis during September 2017-April 2021Exclusion Criteria:- Patients diagnosed with other forms of psoriasis other than plaque-type

Interested in this study? View the official listing for contact and enrollment details.

View on ClinicalTrials.gov

Source: ClinicalTrials.gov (NCT05650060). StuddyBuddy aggregates publicly available trial information.